An interventional study of Moisturizing while in shower/bath and Moisturizing after towel drying in Atopic Dermatitis (AD) and Atopic Dermatitis (Eczema), sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of British Columbia · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 225 studies in Dermatitis, Atopic with a site in Canada — 18 open to participants now, 44 under way, 13 of them phase 3. Dermatitis, Atopic · Canada.
Among the 225 studies in Dermatitis, Atopic with a site in Canada, this one is the 193rd largest by planned enrollment of the 207 interventional ones that give a count, is the only one that started in 2027, is one of 9 with no phase, reaches primary completion later than 19 of the 43 other live ones, and was the 217th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →18 of the 225 studies in Dermatitis, Atopic with a site in Canada are open now. Recruiting first, the newest first:
Triveni Bio · Sites in Canada, United States, Ukraine
Ages 18–75
Pfizer · Sites in Canada, United States, Japan and 1 more country
Ages 12+
Pfizer · Sites in Canada, United States, Japan
Ages 12+
Apollo Therapeutics Ltd · Sites in Canada, United States, Bulgaria and 5 more countries
Ages 18–65
Pfizer · Sites in Canada, United States, Bulgaria and 6 more countries
Ages 18–64
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
225 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 108 · Phase 3 70 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 206 across the 207 interventional studies, 305 across the 17 observational. Of the 178 that completed or were terminated, 120 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
206 of 225 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 2 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
14 of the studies in Dermatitis, Atopic with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT06182436St. Justine's HospitalVirtual Reality for Pain Management During Dupilumab Injection | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 225 studies in Dermatitis, Atopic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Skin moisturization is important for patients with atopic dermatitis, commonly known as eczema. Moisturizing right after bathing is widely accepted as the best method to keep skin hydrated. However, there is conflicting research on the timing of moisturizing. The goal of this clinical study is to evaluate the preference of moisturizing while showering/bathing compared to after towel drying in adolescents aged 12-18 with eczema. The main question it aims to answer are:
Researchers will compare applying moisturizer while in the shower/bath to after towel drying and to which technique is preferred among participants and if there are different effects on eczema and skin hydration.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Moisturizing while in shower/bath
Behavioral: Moisturizing after towel drying
Applying moisturizer in the shower/bath.
Applying moisturizer out of the shower/bath after towel drying.
Proportion of Participants Preferring Each Moisturization Technique
Participant reported preference of moisturization technique
Time frame: Through study completion, an average of 2 months.
Skin Hydration Level
Skin electrical capacitance measured using Corneometer® CM825 as an indicator of skin hydration.
Time frame: Through study completion, an average of 2 months.
Eczema Severity Score
Eczema severity will be assessed by clinicians using the Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD™). Scores range from 1 to 4, with higher scores indicating more severe eczema/atopic dermatitis (worse outcome).
Time frame: Through study completion, an average of 2 months.
Itch Intensity
Itch intensity will be assessed using a patient-reported Numeric Rating Scale (NRS) ranging from 1 to 10, where higher scores indicate greater itch severity (worse outcome). Participants will report both average itch and worst itch experienced within the past 24 hours.
Time frame: Through study completion, an average of 2 months.
Plan to share: No — Individual participant data will not be shared, but aggregated data from all participants will be shared.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for May 2027, 4 months later.
Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.
Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Dec 2025 → Jan 2027, primary completion Dec 2026 → May 2027 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →